
    
      The study is an open label study of orally-administered ivacaftor in subjects with chronic
      bronchitis and/or bronchiectasis. Subjects will be administered the study drug ivacaftor 150
      mg twice daily (BID). The study drug is commercially available and will be purchased by the
      participant.
    
  